Efficacy and safety of Telikibart for moderate to severe atopic dermatitis: a randomized placebo-controlled, phase Ⅲ trial (EADV 2026) - Aug 6, 2026 - Abstract #P2784; AS-1262; Pres time: Sep 30, 2026; Location: ePoster Area; P3 | "Introduction Telikibart (GR1802) is a fully human monoclonal antibody that specifically targets the interleukin-4 receptor alpha (IL-4Rα) subunit, featuring a unique epitope and structural characteristics distinct from dupilumab. The safety profile was mild and tolerable. EASI-75, ≥75% improvement in Eczema Area and Severity Index; IGA 0/1, Investigator's Global Assessment of clear/almost clear skin; LS, Least squares; EASI-90, ≥90% improvement in Eczema Area and Severity Index; AD, atopic dermatitis; SE, standard error; SD, standard deviation; %BSA, percent of total body surface area; PP-NRS, Peak Pruritus Numerical Rating Scale; DLQI, Dermatology Life Quality Index; POEM, Patient-Oriented Eczema Measure; SCORAD, Scoring Atopic Dermatitis Index; CI, confidence interval."
Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL4R
|
|
Shangshang Wang 1; LIMING WU 2; Yumei Li 3; Wenzhong Wu 4; Aijun Chen 5; Furen Zhang 6; Guannan Zhu 7; Jinyan Wang 8; Jianping Zhang 9; Yangfeng Ding 10; Juan Su 11; Lixia Zhang 12; Bing Liu 13; Wenlin Yang 14; Aihua Wei 15; Lunfei Liu 16; Lin Chen 17; Yan Zhang 18; Yunfeng Hu 19; Yuzhen Li 20; Qingchun Diao 21; Meiying Jiang 22; Kunpeng Bian 23; Ruzhi Zhang 24; Zaixing Wang 25; Xiaoming Liu 26; Naihui Zhou 27; Daxing Cai 28; Yan Liu 29; Xu Yao 30; Haixia Jing 31; Guangwen Yin 32; Chao Ji 33; Xiaoyan Chen 34; Rixin Chen 35; Litao Zhang 36; Bin Yin 37; Shanshan Li 38; Yi Zhao 39; Jianjun Qiao 40; Jing Yang 41; Guoqiang Zhang 42; Siping Zhang 43; Xinxiang Lv 44; Guanzhi Chen 45; Zhiming Li 46; Tiechi Lei 47; Xu Jinhua 1
|